Annalisa D’Andrea
Directeur/Membre du Conseil chez Engimmune Therapeutics AG
Profil
Annalisa D’Andrea is currently a Non-Executive Director at Engimmune Therapeutics AG since 2023 and a Venture Partner at Longwood Fund Management LLC since 2021.
Previously, she held positions as an Executive Director & Head-Discovery Biology at SRI International, Vice President & Global Head-Discovery at Roche Holding AG, Chief Scientific Officer at Kiniksa Pharmaceuticals Ltd., and President & Chief Scientific Officer at ImmuneID, Inc. Ms. D’Andrea holds a doctorate degree from the University of Florence and an undergraduate degree from the University of Siena.
Postes actifs de Annalisa D’Andrea
| Sociétés | Poste | Début |
|---|---|---|
Engimmune Therapeutics AG
 Engimmune Therapeutics AG Packaged SoftwareTechnology Services Engimmune Therapeutics AG is a developer of off-the-shelf soluble T-cell receptor drugs to treat solid tumors. The company is based in Allschwil, Switzerland. The Swiss company's proprietary platform technologies enable them to engineer stable, multi-specific TCRs that have high affinity for target cancer antigens and trigger a potent and durable anti-cancer T-cell response without causing damage to healthy cells. The company was founded in 2021 as a spin-off of ETH Zurich from technologies developed by Dr. Rodrigo Vazquez-Lombardi and Professor Sai Reddy. Lars Nieba has been the CEO of the company since 2023. | Directeur/Membre du Conseil | 24/05/2023 |
Longwood Fund Management LLC
 Longwood Fund Management LLC Investment ManagersFinance Longwood Fund Management LLC (Longwood Fund) is a venture capital firm founded in 2010 by Christoph H. Westphal, Michelle Detwiler and Richard H. Aldrich. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 01/03/2021 |
Anciens postes connus de Annalisa D’Andrea
| Sociétés | Poste | Fin |
|---|---|---|
ImmuneID, Inc.
 ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | President | - |
| ROCHE HOLDING AG | Corporate Officer/Principal | - |
SRI International
 SRI International Miscellaneous Commercial ServicesCommercial Services SRI International provides contract research and development services. It is an independent, nonprofit research institute conducting client-sponsored research and development for government agencies, commercial businesses, foundations, and other organizations. The company was founded in 1946 and is headquartered in Menlo Park, CA. | Directeur/Membre du Conseil | - |
| KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC | Directeur Technique/Scientifique/R&D | - |
Formation de Annalisa D’Andrea
| University of Florence | Doctorate Degree |
| University of Siena | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ROCHE HOLDING AG | Health Technology |
| Entreprise privées | 5 |
|---|---|
SRI International
SRI International Miscellaneous Commercial ServicesCommercial Services SRI International provides contract research and development services. It is an independent, nonprofit research institute conducting client-sponsored research and development for government agencies, commercial businesses, foundations, and other organizations. The company was founded in 1946 and is headquartered in Menlo Park, CA. | Commercial Services |
Longwood Fund Management LLC
Longwood Fund Management LLC Investment ManagersFinance Longwood Fund Management LLC (Longwood Fund) is a venture capital firm founded in 2010 by Christoph H. Westphal, Michelle Detwiler and Richard H. Aldrich. The firm is headquartered in Boston, Massachusetts. | Finance |
Kiniksa Pharmaceuticals Ltd.
 Kiniksa Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Kiniksa Pharmaceuticals International Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA. | Health Technology |
ImmuneID, Inc.
ImmuneID, Inc. Miscellaneous Commercial ServicesCommercial Services ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021. | Commercial Services |
Engimmune Therapeutics AG
Engimmune Therapeutics AG Packaged SoftwareTechnology Services Engimmune Therapeutics AG is a developer of off-the-shelf soluble T-cell receptor drugs to treat solid tumors. The company is based in Allschwil, Switzerland. The Swiss company's proprietary platform technologies enable them to engineer stable, multi-specific TCRs that have high affinity for target cancer antigens and trigger a potent and durable anti-cancer T-cell response without causing damage to healthy cells. The company was founded in 2021 as a spin-off of ETH Zurich from technologies developed by Dr. Rodrigo Vazquez-Lombardi and Professor Sai Reddy. Lars Nieba has been the CEO of the company since 2023. | Technology Services |
